The C3 inhibitor Cp20 is a member of the compstatin family (26), which also includes the clinical therapeutic pegcetacoplan that is meanwhile approved for the treatment of PNH and geographic atrophy and the candidate drug AMY-101 (Cp40) (20, 22). The gene discussed is C3; the disease is paroxysmal nocturnal hemoglobinuria.